Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the Jefferies London Healthcare Conference. The presentation will be available on-demand from November 18 at 8:00 AM GMT until November 19 at 5:00 PM GMT. Investors can access the presentation via the Company's website. Nabriva specializes in developing anti-infective agents, including XENLETA® for treating community-acquired bacterial pneumonia and CONTEPO™ for complicated urinary tract infections. The company has also partnered with Merck to market SIVEXTRO® in the U.S.

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the Jefferies London Healthcare Conference. The presentation will be available on-demand beginning on Thursday, November 18 at 8:00am GMT / 3:00am ET through Friday, November 19 at 5:00pm GMT / 12:00pm ET. Management will host investor meetings on Thursday and Friday, November 18-19, 2021.

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com. A replay of the webcast will be available for 90 days.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com

For Media
Andrea Greif
Ogilvy
andrea.greif@ogilvy.com
914-772-3027

FAQ

When will Nabriva Therapeutics present at the Jefferies London Healthcare Conference?

Nabriva Therapeutics will present at the Jefferies London Healthcare Conference from November 18 at 8:00 AM GMT until November 19 at 5:00 PM GMT.

How can investors access the Nabriva Therapeutics presentation?

Investors can access the Nabriva Therapeutics presentation on the Company's website under the 'Investors' section, specifically in the 'Events and Presentations' tab.

What products does Nabriva Therapeutics develop?

Nabriva Therapeutics develops anti-infective agents, including XENLETA® for community-acquired bacterial pneumonia and CONTEPO™ for complicated urinary tract infections.

What is the partnership between Nabriva and Merck?

Nabriva has an exclusive agreement with Merck to market, sell, and distribute SIVEXTRO® in the United States and certain territories.

What is the significance of the Nabriva presentation at the conference?

The presentation will provide an overview and business update on Nabriva's developments in anti-infective therapies, highlighting its innovative products.